Pre-Open Stock Movers 06/15: (CLSD) (OCGN) (AMPE) Higher; (PDSB) (PTGX) (PING) Lower (more...)
- Wall Street surges to all-time closing high on earnings, economic revival
- Was Intel's (INTC) Second Quarter a Speedbump or Inflection?
- Twitter (TWTR) Gains After Beating Q2 Estimates, Analysts Raise PTs as Brand Recovery Accelerates
- U.S. dollar on track for second week of gains; Fed meeting in focus
- Snap (SNAP) Surges 17% After Smashing Q2 Views Across the Board to Yield a Dozen Price Target Hikes
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Pre-Open Stock Movers:
Clearside Biomedical, Inc. (NASDAQ: CLSD) 35% HIGHER; announced today positive safety results from Cohort 1 of OASIS, its ongoing Phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) administered by suprachoroidal injection via Clearsides SCS Microinjector® in six patients (n=6) with neovascular age-related macular degeneration (wet AMD).
PDS Biotechnology Corporation (Nasdaq: PDSB) 17.6% LOWER; commenced an underwritten public offering of shares of its common stock.
Ocugen, Inc. (NASDAQ: OCGN) 15.8% HIGHER; announced that it has selected Jubilant HollisterStier of Spokane, Washington as its manufacturing partner for COVAXIN to prepare for potential commercial manufacturing of COVAXIN for the US and Canadian markets.
Ampio Pharmaceuticals (NYSE: AMPE) 7.8% HIGHER; announced it has received regulatory approval to expand enrollment of its AP-019 Phase II study to India. The study will utilize inhaled Ampion to treat those suffering from respiratory distress due to COVID-19.
Protagonist Therapeutics, Inc. (Nasdaq: PTGX) 6.2% LOWER; announced that it has commenced an underwritten public offering of $100,000,000 of shares of its common stock.
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) 6% HIGHER; announced the presentation of preliminary Phase 1 data from the single-dose portion of the study at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Virtual Annual Meeting. The presentations and posters highlight the potential of Fusion's targeted alpha therapies (TATs) to enable delivery of alpha particle emitting isotopes (225Ac) to targeted tumor cells.
Ping Identity Holding Corp. (NYSE: PING) 4.6% LOWER; announced the commencement of an underwritten public offering of 6,000,000 shares of common stock by investment funds affiliated with Vista Equity Partners.
Mogo Finance Technology (NASDAQ: MOGO) 4.6% HIGHER; BTIG initiates coverage with a Buy rating and a price target of $13.00.
Ellington Residential Mortgage REIT (NYSE: EARN) 4% LOWER; announced that it has commenced a public offering of 575,000 common shares and that a selling shareholder, Blackstone Tactical Opportunities EARN Holdings L.L.C., intends to offer 2,675,000 common shares in the offering.
Arbor Realty Trust, Inc. (NYSE: ABR) 3.2% LOWER; announced today that it plans to make a public offering of 6,000,000 shares of its common stock. In connection with the offering, the Company intends to grant the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock.
Novavax (NASDAQ: NVAX) 3.2% LOWER; discloses a $500 million at-the-market offering via B.Riley
C4 Therapeutics, Inc. (Nasdaq: CCCC) 3% LOWER; announced that it has launched a proposed public offering of 4,250,000 shares of its common stock.
Spirit Airlines (NYSE: SAVE) 2.9% HIGHER; Citi upgraded from Neutral to Buy with a price target of $42.00 (from $40.00).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pre-Open Stock Movers 07/23: (SCKT) (VNE) (ALZN) Higher; (EDU) (TAL) (GOTU) Lower (more...)
- Canaccord Genuity Raises PT on Apple (AAPL) to $175 on Expectations of Strong Q3 Results
- Pre-Open Stock Movers 07/21: (CEMI) (LE) (SDC) Higher; (SNBR) (FOUR) (MGTA) Lower (more...)
Create E-mail Alert Related CategoriesSpecial Reports
Related EntitiesCiti, Pre-Open Losers, Pre-Open Winners, Pre Market Movers, BTIG
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!